Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2006-05-16
2006-05-16
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C424S001650, C424S001730, C424S001890, C549S006000
Reexamination Certificate
active
07045115
ABSTRACT:
An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof:wherein R1denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2denotes hydrogen, hydroxyl or a halogen substituent, R3denotes hydrogen or fluorine substituent, R4denotes oxygen, sulfur, or a methylene substituent, and R5denotes a radioactive halogen substituent.The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.
REFERENCES:
patent: 5077034 (1991-12-01), Kassis et al.
patent: 5422345 (1995-06-01), Dougan
patent: 5703056 (1997-12-01), Blasberg et al.
patent: 5720935 (1998-02-01), Kassis et al.
patent: 0 421 777 (1991-04-01), None
patent: WO 96/28190 (1996-01-01), None
patent: WO 96/12508 (1996-05-01), None
patent: WO 96/23806 (1996-08-01), None
patent: WO 96/28190 (1996-09-01), None
patent: WO 96/44646 (1996-09-01), None
patent: WO 96/41648 (1996-12-01), None
patent: WO 01/054439 (2001-01-01), None
Yoshimura et al. (1997), J. Med. Chem., vol. 40, pp. 2177-2183.
Vaidyanathan et al., “Preparation of 5-[131l]lodo- and 5-[211At] Astato-1-(2-Deoxy-2-Fluoro-β-D-Arabinofuranosy) Uracil by a Halodestannylation Reaction,” Nuclear Medicine & Biology, vol. 25, p. 487-496, 1998.
Machida et al., “Anti-herpesvirus Activity Profile of 4′-thioarabinofuranosyl Purine and Uracil Nucleosides and Activity of 1-β-D-2′-thioarabinofuranosyl Guanine And 2,6-diaminopurine Against Clinical Isolates of Human Cytomegalovirus,” Antiviral Research 39 (1998), pp. 129-137.
O'Donoghue, “Strategies for Selective Targeting of Auger Electron Emitters to Tumor Cells,” The Journal of Nuclear Medicine, vol. 37, No. 4, Apr. 1996, pp. 3S-6S.
Lu et al., “Synthesis of [76Br] Bromofluorodeoxyuridine and Its Validation With Regard to Uptake, DNA Incorporation, and Excretion Modulation in Rats,” the Journal of Nuclear Medicine, vol. 41, No. 10, Oct. 2000, pp. 1746-1752.
Ganesan Vaidyanathan et al., Preparation of 5-[131l]lodo- and 5-[211At] Astato-1-(2-Deoxy-2-Fluoro-β-D-Arabinofuranosyl) Uracil by a Halodestannylation Reaction, Nuclear Medicine & Biology, vol. 25, pp. 487-496, 1998.
Y. Yoshimura, et al., “A facile, alternative syntheses of a 4′-thiorabinonucleosides and their biological activities,” J Med Chem, 1997, Jul. 4, 40(14) abstract only.
Hayashi Akio
Toyohara Jun
Fitch Even Tabin & Flannery
Jones Dameron L.
Nihon Medi+Physics Co., Ltd.
LandOfFree
Drugs for the diagnosis of tissue-reproductive activity or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drugs for the diagnosis of tissue-reproductive activity or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drugs for the diagnosis of tissue-reproductive activity or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559211